Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
- 1 February 2000
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 73 (2) , 314-320
- https://doi.org/10.1016/s0015-0282(99)00524-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Quantitative Gonadotropin-Releasing Hormone Gene Expression and Immunohistochemical Localization in Human Endometrium Throughout the Menstrual Cycle1Biology of Reproduction, 1998
- The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mgHuman Reproduction, 1998
- Possible direct effect of gonadotropin releasing hormone on human endometrium and deciduaLife Sciences, 1998
- Gene expression of gonadotrophin-releasing hormone, but not its receptor, in human endometrium and deciduaMolecular and Cellular Endocrinology, 1997
- A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surgeFertility and Sterility, 1994
- The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer programFertility and Sterility, 1994
- Control of the preovulatory luteinizing hormone surge by gonadotropin-releasing hormone antagonists Prospects for clinical applicationTrends in Endocrinology & Metabolism, 1994
- The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centresHuman Reproduction, 1992
- Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulationFertility and Sterility, 1991
- Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levelsFertility and Sterility, 1991